"Onpro® allowed me to have the day off after chemo. I could just focus on self-care, getting better, feeling better, and getting the treatment that I needed, but in the comfort of my own home."
"The best part of using Neulasta® Onpro® is that I get the medication I need, while also protecting myself from other risks—at the hospital, doctor's office, etc.—that would cause a delay in my chemotherapy."
"Neulasta® Onpro® has allowed me to keep up with my chemo plan because I've not had to worry about my white blood cell count. It has stayed high enough where I've been able to keep going."
Not having to return to the doctor’s office the day after chemotherapy just for an injection was the most important factor for patients when choosing a G-CSF3,§
Patients also valued how much experience their doctor has with the G-CSF they would receive and being informed by the doctor or nurse of all available ways to receive the G-CSF3
*In a key study of 928 patients with breast cancer, when given once every chemotherapy cycle, 17% of patients got infections when not treated with Neulasta®—while only 1% of patients got infections when treated with Neulasta®.5
†2016 data from interviews with oncology patients who have had experience with Neulasta® (N = 227, PFS [n = 150], Neulasta® Onpro® [n = 77]).
Patients who had received Neulasta® via Neulasta® Onpro® were asked to answer the question: Based on your personal experience getting your Neulasta® with Neulasta® Onpro®, if your doctor said you needed to use Neulasta® again in the future, would you request getting it with Neulasta® Onpro® again?3
‡Data from interviews with oncology nurses (N = 250) conducted in October 2016. Respondents were asked if they agree with this statement: Based on my Neulasta® Onpro® experience, when my patients are appropriate for Neulasta® (PFS or Neulasta® Onpro®), I would choose Neulasta® Onpro®.4
§November 2016 data from interviews with oncology patients who have had experience with Neulasta® (N = 227, PFS [n = 150], Neulasta® Onpro® [n = 77]). Patients were asked a multiple-choice selection prompt: If your doctor felt you should receive a G-CSF medication, please select the 3 most important factors to you (other than safety and how well it works) when considering G-CSF care to boost your white blood cell count after chemotherapy. Patients then completed a follow-up prompt: Of the 3 most important factors you selected, we would like to know which is the most important. Please rank these from most important (1) to least important (3).3
FN = febrile neutropenia; G-CSF = granulocyte colony-stimulating factor; PFS = prefilled syringe.
Acute Respiratory Distress Syndrome (ARDS)
Serious Allergic Reactions
Allergies to Acrylics
Use in Patients With Sickle Cell Disorders
Capillary Leak Syndrome (CLS)
Potential for Tumor Growth Stimulatory Effects on Malignant Cells
Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) in Patients With Breast and Lung Cancer
Potential Device Failures
Most common adverse reactions
Please see Neulasta® full Prescribing Information.
Neulasta® Injection: 6 mg/0.6 mL in a single-dose prefilled syringe for manual use only.
Neulasta® Injection: 6 mg/0.6 mL in a single-dose prefilled syringe co-packaged with the on-body injector (OBI) for Neulasta® (Neulasta® Onpro® kit).
Special Instructions for the On-body Injector (OBI) for Neulasta®
A healthcare provider must fill the on-body injector (OBI) with Neulasta® using the co-packaged prefilled syringe and then apply the OBI to the patient’s skin (abdomen or back of arm). The back of the arm may only be used if there is a caregiver available to monitor the status of the OBI. Approximately 27 hours after the OBI is applied to the patient’s skin, Neulasta® will be delivered over approximately 45 minutes. A healthcare provider may initiate administration with the OBI on the same day as the administration of cytotoxic chemotherapy, as long as the OBI delivers Neulasta® no less than 24 hours after the administration of cytotoxic chemotherapy.
The prefilled syringe co-packaged in the Neulasta® Onpro® kit contains additional solution to compensate for liquid loss during delivery through the OBI. If this syringe is used for manual subcutaneous injection, the patient will receive an overdose. If the prefilled syringe for manual use is used with the OBI, the patient may receive less than the recommended dose.
Do not use the OBI to deliver any other drug product except the Neulasta® prefilled syringe co-packaged with the OBI. Use of the OBI has not been studied in pediatric patients.
The OBI should be applied to intact, non-irritated skin on the arm or abdomen.
A missed dose could occur due to an OBI failure or leakage. Instruct patients using the OBI to notify their healthcare professional immediately in order to determine the need for a replacement dose of pegfilgrastim if they suspect that the device may not have performed as intended. If the patient misses a dose, a new dose should be administered by single prefilled syringe for manual use as soon as possible after detection.
Review the Patient Information and Patient Instructions for Use with the patient and provide the instructions to the patient.
Refer to the Healthcare Provider Instructions for Use for the OBI for full administration information.
1. Yang BB, et al. Cancer Chemother Pharmacol. 2015;75:1199-1206. 2. Neulasta® (pegfilgrastim) Prescribing Information, Amgen. 3. Kirshner JJ, et al. Support Care Cancer. 2018;26:1323-1334. 4. Yang BB, et al. Clin Pharmacokinet. 2011;50:295-306. 5. Haegerstam GA. Acta Orthop Scand. 2001;72:308-317. 6. Schweizerhof M, et al. Nat Med. 2009;15:802-807.
1. Data on file, Amgen; 2021. 2. Data on file, Amgen; 2020. 3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myeloid Growth Factors V.1.2021. ©National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed April 25, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 4. Smith TJ, et al. J Clin Oncol. 2015;33:3199-3212. 5. Martin M, et al. N Engl J Med. 2005;352:2302-2313. 6. Younis T, et al. Support Care Cancer. 2012;20:2523-2530. 7. Perjeta (pertuzumab) Prescribing Information, Genentech, Inc. 8. Schneeweiss A, et al. Ann Oncol. 2013;24:2278-2284. 9. Cerchione C, et al. Support Care Cancer. 2017;25:839-845. 10. Ösby E, et al. Blood. 2003;101:3840-3848. 11. Delarue R, et al. Lancet Oncol. 2013;14:525-533. 12. Ohe Y, et al. Ann Oncol. 2007;18:317-323. 13. Swain SM, et al. N Engl J Med. 2010;362:2053-2065. 14. Schiller JH, et al. N Engl J Med. 2002;346:92-98. 15. Yoshimura N, et al. J Thorac Oncol. 2009;4:371-375. 16. Kongsted P, et al. Urol Oncol. 2015;33:494.e15-494.e20. doi:10.1016/j.urolonc.2015.06.022. 17. Vogel CL, et al. J Clin Oncol. 2005;23:1178-1184. 18. Moreau M, et al. Ann Oncol. 2009;20:513-519. 19. Lyman GH, et al. Leuk Lymphoma. 2003;44:2069-2076. 20. Lyman GH, et al. J Clin Oncol. 2004;22:4302-4311. 21. Klastersky J, et al. J Clin Oncol. 2000;18:3038-3051. 22. Chao C, et al. Ann Oncol. 2014;25:1821-1829. 23. Takenaka Y, et al. Support Care Cancer. 2013;21:2861-2868. 24. Shayne M, et al. Cancer. 2007;110:1611-1620. 25. Intragumtornchai T, et al. Leuk Lymphoma. 2000;37:351-360. 26. Family L, et al. J Clin Oncol. 2016;34. Abstract 6559. 27. Pettengell R, et al. Br J Haematol. 2008;144:677-685. 28. American Cancer Society. Watching for and Preventing Infections. https://www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/low-blood-counts/infections/preventing-infections-in-people-with-cancer.html. Accessed December 20, 2021. 29. Neulasta® (pegfilgrastim) Prescribing Information, Amgen.
1. Data on file, Amgen; 2021. 2. Mahtani RL, et al. A multicenter, prospective, observational study to determine the incidence of febrile neutropenia (FN), persistence and G-CSF utilization among cancer patients at high risk for FN receiving pegfilgrastim by an on-body injector (OBI) versus other FN-prophylaxis strategies. Poster presented at: San Antonio Breast Cancer Symposium®, Virtual. 3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myeloid Growth Factors V.1.2021. ©National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed April 5, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 4. Data on file, Amgen; 2020. 5. Lyman GH. J Natl Comr Canc Netw. 2009;7:2612-2615.
1. Data on file, Amgen; 2021.
1. Data on file, Amgen; ; 2020. 2. Data on file, Amgen; ; 2020. 3. Data on file, Amgen; ; 2020. 4. Data on file, Amgen; 2016. 5. Vogel CL, et al. J Clin Oncol. 2005;23(6):1178-1184.
1. Vogel CL, et al. J Clin Oncol. 2005;23(6):1178-1184.